Evaluation of SEREX defined antigens by mRNA expression analysis in breast cancer tissues of Egyptian patients

Ali Mohamed Ali Eldib

ABSTRACT

The identification of human cancer antigens has opened new approaches to the development of cancer vaccines. Characterization of the defined antigens including mRNA expression analysis, protein analysis, antibody response and epitope identification are important to assess the value of those antigens. The aim of the present work is to identify tumor specific or tumor associated antigens by serological analysis of recombinant cDNA expression library (SEREX). Different cancer cell lines and normal testis were used as a source of cDNA library in this study including lung cancer, renal cancer, colon cancer and ovarian cancer in addition to a testicular library. For immunoscreening, autologous as well as allogeneic sera were obtained. By autologous immunoscreening, we previously reported the SEREX analysis of the lung adenocarcinoma cell line OU-LU-6 including the identification of the cancer/testis antigen XAGE-1b. We also reported the SEREX analysis of the lung adenocarcinoma cell lines OU-LU-17 and OU-LU-11. This work focused on the defined SEREX genes by autologous and allogeneic immunoscreening of the renal cancer cell line RC-1. The total number of defined clones was 51 representing 39 different genes named OY-REN-1 through OY-REN-39. The vast majority of clones identified by SEREX are ubiquitously expressed genes. In the renal cancer cell line RC-1, OY-REN-1, 3, 18, 29 and 31 genes were the most frequently isolated (3 of 51), subsequently, OY-REN-2 and 30 were the second most frequent isolated genes, each was represented by 2 of 51 clones. All other genes were represented by a single clone. Within the isolated genes, protein kinase c, Iota (PKCI) which clones had a deletion compared to sequences in the database which might give the chance to identify a new isoform. mRNA expression analysis of PKCI in normal as well as breast cancer tissues showed no cancer specific characteristics compared to the cancer/testis antigen XAGE-1b and c variants. Very interestingly, XAGE-1b antigen showed a significantly high frequency of expression in breast cancer tissues (5/10) taken from Egyptian patients. Using the SEREX defined antigens for mRNA expression in breast cancer tissues may aid the development of diagnostic and immunotherapeutic agents for patients with breast cancer in Egypt.

Key words: SEREX; Lung Cancer; Colon Cancer; Renal Cancer; Testicular Library.

INTRODUCTION

The identification of tumor-associated antigens and their cognate autoantibodies is a promising strategy for diagnosis, monitoring and immunotherapy of human cancer (Christoph et al., 2001). The immune response to the incidence of cancer is elicited in humans, as demonstrated in part by the identification of autoantibodies against a number of tumor-associated antigens in sera from patients with different types of cancer (Desmetz et al., 2009). Since, studies of the cellular and humoral immune response to cancer have revealed an extensive repertoire of tumor antigens recognized by the immune system, collectively termed the cancer immunome.
(Sang-Yull et al., 2003). The possibility that cancers could be eradicated by specific immune response and that the immune system could be stimulated to effectively kill tumor or malignant cells is the most desired goal for all studies worldwide (Olivera 2003). The idea is that the effective and specific antitumor response by the host immune system can be induced by immunization with tumor specific antigens is our marginal base to identify tumor antigens, which can work as therapeutic vaccine to stop the growth of existing tumors, prevent the recurrence of cancer by killing or eliminating cancer cells (Howard et al., 2004).

Serological analysis of recombinant cDNA expression libraries (SEREX) using tumor mRNA and autologous patient serum provides a powerful approach to identify immunogenic tumor antigens (Chen et al., 1997, Eldib et al., 2004). Since, SEREX analysis has been identified a large number of antigens in almost in all cancer examined, including cancer/testis (CT) antigen (NY-ESO-1, SSX, SCP-1). CT antigens have received a particular attention, at least in part, because of their restricted expression in normal tissues; therefore, CT antigens are potential targets for vaccine-based immunotherapies (Sang-Yull et al., 2003). In general, CT antigens are expressed in 20–40% of specimens from a given tumor type (Sahin et al., 1998, Tadashi et al., 2011).

In this study, we performed the SEREX analysis to identify tumor associated and tumor specific antigens by different cancer types. mRNA expression analysis for XAGE-1 and PKCI was then conducted using breast cancer tissues. Some of our SEREX defined antigens need further analysis to clarify whether they are candidates for diagnosis or therapy.

MATERIALS AND METHODS

Tissues, cell lines and sera

All cell lines were obtained from Immunology Department, Okayama University, Japan. OU-LU-6, 17 and 11 are lung cancer cell lines established from pleural effusion of 3 different patients with adenocarcinoma. RC-1 is a renal cancer cell line obtained from a patient with clear cell carcinoma. The colon cancer cell line AH-C-164 was from a patient with adenocarcinoma. A fresh tissue from normal testis was used to prepare the testicular library. Autologous and allogeneic sera used in the study were obtained from cancer patients in accordance with the Okayama university guidelines after receiving written informed consent. Breast cancer specimens were surgically obtained from patients at Damanhour Oncology Center and at Aldelengat General Hospital. Collection of tissues and sera was agreed upon by patients and healthy donors, after provision of written, informed consent.

Preparation of cDNA libraries

mRNA was purified from each cell line independently, using a Quick Prep mRNA Purification Kit (Amersham Pharmacia, Piscataway, NJ). Each cDNA expression library was prepared in a λZAP Express vector using a cDNA library kit (Stratagene, La Jolla, CA).

Immunoscreening of the cDNA library and characterization of selected immune-reactive clones

Each cDNA expression library was screened with autologous and/or allogeneic patient serum. In brief, serum samples diluted 1:10 were pre-absorbed with lysate from Escherichia coli Y1090/Y1089 and bacteriophage-infected Y1090 coupled to sepharose 4B (Bio Dynamics Lab, Inc., Tokyo, Japan). Nitrocellulose membranes containing the phage plaques at a density of about 4,000 pfu/140 mm plate were incubated overnight at room temperature with the pre-absorbed serum diluted 1:200 (Fig. 1). Reacted clones were detected by peroxidase-conjugated goat anti-human IgG (Jackson Immuno Research, West Grove, PA) and visualized with 3-3′-diaminobenzidine (Sigma, St. Louis, MO). The selected immunoreactive clones were tested for reactivity against diluted sera using the same plaque assay. A negative clone randomly chosen was included in each assay as a negative control.

![Fig. 1: Sample nitrocellulose membranes of 3 different sizes used for immunoscreening of a cDNA library with cancer patient serum and phage plaque assay for petit serology. Recombinant phages were spread on agar plates at a density of about 4000 pfu, clones were transferred to 140 mm nitrocellulose membranes, then incubated overnight with the pre-absorbed serum diluted 1:200, positive clones were detected by peroxidase-conjugated goat anti-human IgG (Jackson Immuno Research, West Grove, PA) and visualized by 3-3′-diaminobenzidine (Sigma, St. Louis, MO) (A). Positively reacted clones (+) were picked up and subjected to 2nd screening using the same serum on 80 mm membranes (B). A 3rd screening was conducted using positive clones for monoclonality using 40 mm membranes (C). The frequency of antibody response to SEREX-defined antigens in sera from normal individuals and cancer patients were assessed using phage plaque assay (D-E).](image-url)

Sequence analysis

The positive clones were sub cloned to monoclonality, purified, and excised in vivo to pBK-CMV plasmid forms (Stratagene). Plasmid DNA was prepared using a Quantum Prep Plasmid Miniprep Kit (Bio-Rad, Hercules, CA). The nucleotide sequence of cDNA inserts was determined by an ABI PRISM R310 Genetic Analyzer (PerkinElmer), and sequence alignments were performed with BLAST software and compared with sequences in the GenBank and EST databases http://blast.ncbi.nlm.nih.gov/Blast.cgi and HUGO Gene Nomenclature Committee http://www.genenames.org/index.html.

mRNA expression analysis by RT-PCR

Using specific primers of some SEREX defined antigens, and tumor tissues from Egyptian cancer patients. To amplify cDNA segments from tumor and normal tissues, primers for the respective XAGE-1b and XAGE-1c transcripts were used (Eldib et
al., 2004). For PKCI, specific sense and antisense primers were designed (Fig. 2).

Total RNA was isolated from different tumor tissues using an RNeasy Mini Kit (Qiagen, Hilden, Germany). The isolated RNA was reverse-transcribed into a single-strand cDNA using Moloney murine leukemia virus reverse transcriptase (Ready-To-Go You-Prime First-Strand Beads, Amersham Pharmacia) and oligo (DT) 15 as a primer. A normal tissue panel obtained commercially (Clontech, Palo Alto, CA) was also used for PCR reaction. RT-PCR was performed using 30 cycles at an annealing temperature of 60ºC, and the products were analysed by agarose gel electrophoresis. cDNA was tested for integrity by amplification of G3PDH in a 30-cycle reaction.

RESULTS

Molecular characterization of SEREX defined antigens

Schematic representation and a brief summary of SEREX (Serological identification of antigens by recombinant expression cloning) using autologous and/or allogeneic sera and evaluation of tumor antigens are shown in Table 1. SEREX analysis was performed using several cancer cell lines including 3 lung cancer cell lines (OU-LU-6, OU-LU-17 and OU-LU-11), a renal cancer cell line (RC-1), a colon cancer cell line (AH-C-164), an ovarian cancer cell line (O-32) in addition to normal testis as sources of cDNA libraries (Table 1). As shown in table 1, a total number of 202 serum reactive clones representing 144 distinct antigens were totally obtained in autologous and allogeneic immunoscreening.

From the lung cancer cell lines, we isolated a panel of antigens, previously reported (Eldib, et al., 2004, Tadashi et al., 2011). Using those three lung adenocarcinoma cell lines, we isolated a total number of 79 positive clones representing 44 different genes including the cancer/testis XAGE-1b and c transcript variants.

Identification of renal cancer antigens by SEREX

A cDNA library of 2.5x10^6 primary clones was constructed from RC-1 cell line. Four different sera were prepared for the SEREX analysis, including the autologous serum of RC-1. Serum preparation included E.coli lysates absorption treatment and screening with a non-related coda from mouse library. The used sera are RC-1 as an autologous serum, and three allogeneic sera 9-K-b, 9-A-1, and 11-A-9. A total number of about 2.8x10^5 RC-1 clones were immunoscreened consisting of 1x10^5 clones with the autologous serum, and 0.6x10^5 clones with each allogeneic serum (Table 1).

<table>
<thead>
<tr>
<th>Table 1: Summary of autologous and allogeneic immunoscreening of SEREX analysis using cDNA libraries from cancer cell lines and normal tests.</th>
</tr>
</thead>
<tbody>
<tr>
<td>cDNA library</td>
</tr>
<tr>
<td>cDNA source cell line/tissue</td>
</tr>
<tr>
<td>Histology</td>
</tr>
<tr>
<td>Stage of disease</td>
</tr>
<tr>
<td>Primary clones no. of cDNA library</td>
</tr>
<tr>
<td>Total no. of screened clones</td>
</tr>
<tr>
<td>Total no. of positive clones</td>
</tr>
<tr>
<td>Total no. of defined antigens</td>
</tr>
</tbody>
</table>

*We previously reported the SEREX analysis of the lung adenocarcinoma cell line OU-LU-6, Int. J. Cancer: 108, 558-563 (2004).
**We also reported the SEREX analysis of the lung adenocarcinoma cell lines OU-LU-17 and OU-LU-11, Cancer Letters: 301, 57-62 (2011).
1Auto.: autologous serum  2Allo. A (9-K-b), Allo. B (9-A-1) and Allo. C (11-A-9); are 3 allogeneic sera from different renal cancer patients
3Allo. AH-C-164 and 4Allo. KC-18: Allogeneic sera from two colon cancer patients.
5Allo. RC-1: Allogeneic serum from a renal cancer patient screened with the testicular library.
The total number of positive clones isolated from RC-1 library screening with the four renal cancer sera was 51 clones representing 39 genes named OY-REN-1 through OY-REN-39 (Tables 2-5). The database search showed ubiquitous expression characters for all RC-1 genes.

Autologous serum screening led to the isolation of 19 positive clones representing 14 different antigens (Table 2). Of note, OY-REN-1 and 3 genes were the most frequently isolated (3 clones each), subsequently, OY-REN-2 was represented by 2 clones while the rest of genes were represented by a single clone for each (Table 2).

As shown in Tables 3, 4 and 5 using the allogeneic sera these are allogeneic serum A (9-K-b), allogeneic serum B (9-A-1) and allogeneic serum C (11-A-9) from 3 different renal cancer patients for immunoscreening led to the isolation of 16, 12 and 4 positive clones representing 14, 7 and 4 different genes.
respectively. Among the genes defined by the allogeneic serum A, OY-REN-18, the protein kinase C Iota was the most frequently isolated 3 clones (Table 3). All other genes were represented by one clone each. The interesting point in our SEREX research is the presence of a deletion in the sequence of the PKCI clones compared to the sequence in the database, which might give a chance to identify a new isoform. The deletion shifts the ORF and may give a new putative protein (Fig. 2).

Immunoscreening the RC-1 library with the allogeneic serum B led to the isolation of 7 genes represented by 12 clones. OY-REN-29 and 31 were represented by 3 clones each; OY-REN-30 was represented by 2 clones while other genes were represented by one clone each. Using the allogeneic serum C led to the isolation of 4 positive clones representing 4 genes.

XAGE-1b, c and PKCI mRNA expression in breast cancer and normal tissues

For comparison, mRNA expression of XAGE-1b and c transcripts and PKCI was investigated in 10 breast cancer tissues using specific PCR primers (Fig. 3A). RT-PCR was performed at 30 cycles. As shown in Fig. 3A, using the common primer pair X-1 and X-2, a PCR product of 346 bp in length was observed in 5/10 breast cancer tissues. Using X-4 and X-2 for XAGE-1c showed no PCR product. While very faint products of 444 bp in length (4/10) were observed after using PKCI specific primers. In adult normal tissues, PKCI expression was observed ubiquitously (Fig. 3B). The results indicated that XAGE-1b is the predominantly expressed antigen in breast cancer tissues.

### Table 4: Genes identified from the renal cancer cell line RC-1 by screening with allogeneic serum (B).

<table>
<thead>
<tr>
<th>Gene</th>
<th>No. of Clones</th>
<th>Identity/similarities</th>
<th>UniGene cluster</th>
<th>HGNC ID</th>
<th>Chrom.</th>
<th>Expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>OY-REN-29</td>
<td>3/51</td>
<td>ubiquitin B</td>
<td>Hs.356190</td>
<td>12463</td>
<td>17p12-p11.2</td>
<td>Ubiquitous</td>
</tr>
<tr>
<td>OY-REN-30</td>
<td>2/51</td>
<td>heat shock 70kDa protein 4</td>
<td>Hs.90095</td>
<td>5237</td>
<td>5q31.1</td>
<td>Ubiquitous</td>
</tr>
<tr>
<td>OY-REN-31</td>
<td>3/51</td>
<td>zinc finger protein 549 (ZNF549)</td>
<td>Hs.132562</td>
<td>26632</td>
<td>19q13.43</td>
<td>Ubiquitous</td>
</tr>
<tr>
<td>OY-REN-32</td>
<td>1/51</td>
<td>ubiquitin C</td>
<td>Hs.524832</td>
<td>12468</td>
<td>12q24.3</td>
<td>Ubiquitous</td>
</tr>
<tr>
<td>OY-REN-33</td>
<td>1/51</td>
<td>leucine rich repeat interacting protein 1</td>
<td>Hs.471779</td>
<td>6702</td>
<td>2q37.3</td>
<td>Ubiquitous</td>
</tr>
<tr>
<td>OY-REN-34</td>
<td>1/51</td>
<td>bromodomain adjacent to zinc finger domain 1B</td>
<td>Hs.728963</td>
<td>961</td>
<td>7q11.23</td>
<td>Ubiquitous</td>
</tr>
<tr>
<td>OY-REN-35</td>
<td>1/51</td>
<td>cyclin-dependent kinase 6</td>
<td>Hs.119882</td>
<td>1777</td>
<td>7q21-q22</td>
<td>Ubiquitous</td>
</tr>
</tbody>
</table>

The Identity was performed using the Blast software: [http://blast.ncbi.nlm.nih.gov/Blast.cgi](http://blast.ncbi.nlm.nih.gov/Blast.cgi)

### Table 5: Genes identified from the renal cancer cell line RC-1 by screening with allogeneic serum (C).

<table>
<thead>
<tr>
<th>Gene</th>
<th>No. of Clones</th>
<th>Identity/similarities</th>
<th>UniGene cluster</th>
<th>HGNC ID</th>
<th>Chrom.</th>
<th>Expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>OY-REN-36</td>
<td>1/51</td>
<td>enoyl-CoA delta isomerase 2</td>
<td>Hs.15250</td>
<td>14601</td>
<td>6p24.3</td>
<td>Ubiquitous</td>
</tr>
<tr>
<td>OY-REN-37</td>
<td>1/51</td>
<td>ubiquitin specific peptidase 8</td>
<td>Hs.443731</td>
<td>12631</td>
<td>15q21.1</td>
<td>Ubiquitous</td>
</tr>
<tr>
<td>OY-REN-38</td>
<td>1/51</td>
<td>topoisomerase (DNA) II alpha</td>
<td>Hs.156346</td>
<td>11989</td>
<td>17q21-q22</td>
<td>Ubiquitous</td>
</tr>
<tr>
<td>OY-REN-39</td>
<td>1/51</td>
<td>ring finger and CCCH-type domains 2</td>
<td>Hs.533499</td>
<td>21461</td>
<td>9q34</td>
<td>Ubiquitous</td>
</tr>
</tbody>
</table>

The Identity was performed using the Blast software: [http://blast.ncbi.nlm.nih.gov/Blast.cgi](http://blast.ncbi.nlm.nih.gov/Blast.cgi)
PKCI
G3PDH

Fig. 3: RT-PCR analysis (30 cycles) for mRNA expression of XAGE-1b and c transcript variants and the SEREX defined antigen, protein kinase C-iota (PKCI) in breast cancer (B1-B10) tissues (A). Primers used are (X-1 and X-2) for XAGE-1b, (X-4 and X-2) for XAGE-1c, Int J. Cancer: 108, 558-563 (2004). Primers used for (PKCI) are spanning nt 445-888 sense 5‘-ATGGATAGATGAGGAAGGAG and anti-sense 5‘-ATTACTGTCTGTGCATGGTC-3‘. Using the same primer pair for PKCI expression in a normal tissue panel (B). G3PDH was used as internal control.

DISCUSSION

In order to identify human tumor antigens that eliciting high-titer IgG antibodies, serological analysis of recombinant cDNA expression libraries (SEREX) was developed to combine serological analysis with antigen cloning techniques (Sahin et al., 1995) and (Chen et al., 2000). SEREX has contributed greatly to our understanding of the humoral immune response to cancer (Chen 2004). It has led to the identification of a variety of tumor specific and tumor associated antigens, including cancer/testis (CT) antigens (Chen et al., 1997 and Türeci et al., 1998), mutational antigens (Gordan et al., 1998), over-expressed antigens (Brass et al., 1999 and Türeci et al., 1998), differentiation antigens (Scanlan et al., 1999), splice-variant antigens (Jäger et al., 1999), and viral antigens (Türeci et al., 1997). We have done SEREX analysis using several cancer cell lines including 3 lung cancers and a renal cell cancer line, a colon cancer cell line, an ovarian cancer cell line and normal testis. In lung cancer cell lines, a panel of different antigens was isolated, among them XAGE-1 was originally identified by EST database mining (Brinkmann et al., 1999) and found to be highly expressed in normal testis and Ewing’s sarcoma (Liu et al., 2000). The XAGE-1 gene is located on chromosome Xp11.21 - Xp11.22, consists of 4 exons and shows homology to GAGE/PAGE genes (Shimono et al., 2007). It has been reported that there are 4 transcript variants, XAGE-1a, b, c, and d. Within those, XAGE-1b was shown to be the major transcript (Nakagawa et al., 2005; Koizumi et al., 2005). A higher expression of XAGE-1b mRNA was observed in Ewing’s sarcoma and metastatic lesions of melanoma compared to XAGE-1a (Zendman et al., 2002).

We have identified 39 antigens by SEREX analysis of renal cancer represent a diverse group of proteins, including immunoglobulin binding protein (e.g., OY-REN-1), heat shock proteins (e.g., OY-REN-12, 30), RNA binding proteins (e.g., OY-REN-22, 24), microtubule associated proteins (OY-REN-25), and cell division-associated proteins (e.g., OY-REN-14), OY-REN-29, 32 and 37 may be involved in the ubiquitin pathway. Protein kinase C, Iota was identified from a renal cancer cell line (RC1) through immunoscreening of its library with an allogeneic serum in SEREX analysis. Protein Kinase C, Iota was isolated through screening the library with the allogeneic serum 9-K-b, and represented by 3 clones. Sequence analysis of these two clones revealed almost the whole length of the gene. PKC family exists as a family of 9 related gene products that are differentially expressed and that show differences in their co-factor requirements. It is therefore likely that the different isoforms serve different physiological roles (Steinberg et al., 1995).

The functional diversity correlates with a number of structural features predicted from the amino acid sequence of the various isoforms. The PKC family is divided into three major classes: the classical PKCs (a, b, and g isoforms), the novel PKCs (d, e, h, and q isoforms), and the atypical group (z, and i) (Fields et al., 2007). The amino acid sequence of PKC iota showed greatest homology to PKC zeta, with 72% identity overall rising to 84% in the catalytic domain. In contrast, the homology of PKC iota to the other isoforms was less pronounced, with < 53% identity even in the highly conserved catalytic region. Further similarities between PKC zeta and PKC iota included a highly conserved pseudo substrate sequence, the absence of an apparent Ca (2+)-binding region, and the presence of only one cysteine-rich, zinc finger-like domain. PKC iota is included in the atypical subgroup of PKCs whose definitive member is PKC zeta (Murray et al., 2011). The interesting point in our SEREX research was the presence of a deletion in the sequence of the Iota clones compared to the sequence in the database which might give a chance to identify a new isoform. A homology search in GenBank database revealed that 2 genes showed no strong homology indicating novel genes OY-CO-7 and 19. Further prospective studies may help for identifying the function of these 2 genes. Serological analysis for antigens was performed on the basis of their reactivity with sera from healthy donors and cancer patients. All examined antigens were reacted with sera from a subset of healthy donors and cancer patients by phage plaque assay. No RC-1 antigens showed a cancer-restricted recognition pattern (data not shown).

In order to examine the status of XAGE-1 and PKCI mRNA expression and validate it as a potential diagnostic and therapeutic target, mRNA expression analysis in breast cancer was conducted.

In mRNA expression analysis in breast cancer tissues using the known cancer/testis antigen XAGE-1b and c variants and a ubiquitous gene PKCI, the results showed high frequency for XAGE1b while XAGE1c and PKCI showed no expression. These results prove the idea that cancer/testis (CT) antigens are immunogenic proteins expressed predominantly in gametogenic tissue and cancer; they are considered promising target molecules for cancer vaccines (Matthew et al., 2002).

Generally, breast cancers are difficult to distinguish based on histological markers. The results of the present study indicate that XAGE-1b may have prognostic utility and may be a promising molecular target for diagnosis and treatment immunotherapy of breast cancer. This is the first report for mRNA expression profile analysis using cancer/testis antigens (XAGE-1b) in Egyptian patient’s malignant tissues (breast cancer). Such expression profile is a very important step for Egyptian patients. Characterization of those antigens which considered candidate targets for
immunotherapy of tumors will open the door for cancer patients in Egypt in the future for such immunotherapeutic agents.

Further characterization of mRNA and protein analysis governing these and other cancer specific antigens using malignant tissues and samples from Egyptian patients may reveal novel control points leading to development of rational molecular and/or immune-based therapies for breast cancer and other cancer types.

ACKNOWLEDGEMENT

I acknowledge Prof. Eiichi Nakayama, Immunology Department, Graduate School of Medicine, Okayama University, Japan and Dr. Toshiro Ono, Department of Radiation Research, Advanced Science Research Center, Okayama University for continuous help and for providing the lung cancer tissues and primers, also for help completing the SEREX work. Also, I appreciate Dr. Ezzat Mohamed Hassan Abdalla, a surgeon at Damanhour Oncology Center (DOC) and Dr. Abdel-baset salem barghash, a surgeon at Aldelengat General Hospital for providing the breast and Prostate cancer tissues and also the serum samples from the same patients.

REFERENCES


